key: cord-0768437-claiy19m
authors: Dai, Cong; Huang, Yu-hong
title: Letter to the Editor on “Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease Patients During the SARS-CoV-2 Pandemic”
date: 2021-04-29
journal: Dig Dis Sci
DOI: 10.1007/s10620-021-06957-9
sha: 5d06402b12222563936505060938ed5ade91c491
doc_id: 768437
cord_uid: claiy19m

nan

medical consultation and the method of buying drugs before and after the COVID-19 pandemic.

At the same time, 52 (21.8%) patients (14 patients with CD, 32 patients with UC and 6 patients with unclassified IBD) have changed their treatment schedules. Before the COVID-19 pandemic, 53.4% of patients used 5-ASA, 3.7% used corticosteroids, 12.7% used immunosuppressive drugs, and 14.2% used biological agents (Infliximab and Adalimumab). However, 21.8% of patients changed their treatment schedules, 55.3% used 5-ASA, 2.0% used corticosteroids, 11.5% used immunosuppressive drugs, and 14.2% used biological agents during the COVID-19 pandemic. And 31.1% of patients who changed their treatment schedules complained that they could not buy enough drugs or use infliximab on time. The main reason was that many hospitals were unable to open and treat non-COVID-19 patients in the COVID-19 pandemic. Therefore, 41 (17.2%) patients had delayed the use of infliximab, and 36 (87.8%) patients had delayed for more than two weeks. Most of these patients (70.5%) had to stop using biological agents.

In conclusion, we found that the COVID-19 has significantly affected the treatment schedule and medical consultation of patients with IBD treated with biological agents at our unit.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 

Treatment adherence and clinical outcomes of patients with inflammatory bowel disease on biological agents during the SARS-CoV-2 pandemic